Drug Delivery Business

CardioRenal Systems wins FDA breakthrough nod for RenalGuard Therapy device

By

CardioRenal Systems RenalGuard
[Image courtesy of CardioRenal Systems]
CardioRenal Systems announced today that it received FDA breakthrough device designation for its RenalGuard Therapy device.

Milford, Massachusetts-based CardioRenal Systems designed the device for preventing acute kidney injury (AKI). It’s for patients at risk for cardiac surgery-associated AKI.

RenalGuard protects the kidneys with personalized, active hydration. The system maximizes urine output while balancing hydration. It does so through real-time urine output monitoring and IV infusion in a smart re-hydration system.

Get the full story at our sister site, MassDevice.

IN CASE YOU MISSED IT

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].